Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

Exclusion Criteria

• •Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding inclusion
• •Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy \> 2 weeks
• •Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator
• •Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures
• •Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune responses
• •Known Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C seropositivity
• •History of invasive meningococcal disease (confirmed either clinically, serologically, or microbiologically)
• •For Groups 1 and 2: Previous vaccination (including booster) against meningococcal disease, with the exception of the Menactra® or Menomune® vaccination received in trial MTA04, MTA12, MTA19, or MTA21
• •Subjects deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
• •Received oral or injected antibiotic therapy within the 72 hours prior to the blood draw (temporary criteria)